Oncology Division
Alphabetical list (active faculty):   
Nancy L. Bartlett

Nancy L. Bartlett, MD

Koman Professor of Medical Oncology


Department of Medicine

Oncology Division

Medical Oncology

Research Interests

  • Non-Hodgkin's lymphoma
  • Hodgkin's disease
  • Chronic lymphocytic leukemia


  • 314-362-5654 (office)
  • 314-747-5123 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)


My research focuses on the design, conduct, and analysis of clinical trials evaluating new treatments for patients with non-Hodgkin (NHL) or Hodgkin lymphoma (HL), including investigator-initiated, pharmaceutical and cooperative group trials. I have been Vice-Chair of the CALGB/Alliance Lymphoma Committee for more than 10 years, where I have served as PI or Co-PI of several Phase II studies and mentored young investigators during trial design and analysis. I serve as the Principal Investigator of the Washington University/Siteman Cancer Center NCTN U10 grant, engaging senior, mid-level, junior investigators and fellows in the National Clinical Trials Network mission. I work closely with the pharmaceutical company SeaGen testing the anti-CD30 based antibody drug conjugate, brentuximab vedotin (BV), for both HL and NHL including efforts to combine BV with chemotherapy and/or PD-1 inhibitors as first line therapy in HL and with lenalidomide in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Our investigator-initiated phase I/dose expansion study of BV and lenalidomide in relapsed DLBCL serves as the experimental arm of an ongoing company-sponsored randomized Phase 3 study. I have ongoing collaborations investigating immunotherapy approaches for lymphoma including 1) the bispecific antibodies (T-cell engagers) mosunetuzumab and glofitimab for R/R B-cell lymphomas, 2) CAR-T cell therapy in R/R DLBCL, 3) personalized neo-antigen vaccines in combination with nivolumab in R/R follicular lymphoma, 4) anti-CD47 antibodies in R/R B-cell lymphomas, and 5) azacytidine or venetoclax in combination with chemotherapy for DLBCL. In addition to my interest in clinical trial development, I have worked closely with other Washington University investigators on exome sequencing of Hodgkin, follicular and transformed large cell lymphoma.